#TXG hashtag - Bluesky

PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas PerturbAI emerged from stealth on March 17, 2026, releasing the world's largest in vivo CRISPR atlas: an 8 million–cell, brain-wide dataset generated with NVIDIA, Allen Institute for Brain Science, and 10x Genomics (Nasdaq: TXG).The atlas maps thousands of genetic perturbations across hundreds of neuronal cell types, enabling organism-level, circuit-resolved causal genomics and AI-driven therapeutic discovery. PerturbAI closed an oversubscribed pre-seed round in Q3 2025.

1 week ago

#TXG PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas

www.stocktitan.net/news/TXG/perturb-ai-laun...

0 0 0 0

BatzVT 🔜 #TXG

@batzvt.bsky.social

2 weeks ago

Looking forward to #TXG - The Games Expo 2026 this weekend. I hope to see some new and familiar faces. Please come say hi if you see me.

0 0 0 0

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease Study aims to identify single cell immune signatures of disease activity and treatment response to support clinical care. PLEASANTON, Calif., Jan. 12, 2026/ PRNewswire/-- 10 x Genomics, Inc., a leader in single cell and spatial biology, today announced a collaboration with Brigham& Women's Hospital, a world-class academic medical center, to analyze peripheral blood...

2 months ago

#TXG 10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

www.stocktitan.net/news/TXG/10x-genomics-la...

0 0 0 0

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling 10x Genomics (NASDAQ: TXG) announced a multi-year collaboration with Dana-Farber Cancer Institute to analyze tumor samples from hundreds of patients across major solid tumor types using single cell and spatial profiling. The initiative aims to identify biomarkers tied to treatment response, resistance and progression and to define a clinical reporting framework to support precision oncology. 10x also plans to establish a CLIA-certified laboratory to enable assay implementation, analytical validation and future diagnostic services using its Chromium Flex single cell assay and Xenium spatial platform.

2 months ago

#TXG 10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

www.stocktitan.net/news/TXG/10x-genomics-to...

0 0 0 0

10x Genomics Reveals Preliminary Fourth Quarter and Year-End Results for 2025 10x Genomics, a leader in biology technology, has announced preliminary financial results for Q4 and the entirety of 2025, showcasing growth amidst challenges.

2 months ago

10x Genomics Reveals Preliminary Fourth Quarter and Year-End Results for 2025 #United_States #Pleasanton #10x_Genomics #Spatial_Biology #TXG

0 0 0 0

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results 10x Genomics (Nasdaq: TXG) reported preliminary, unaudited select results for Q4 and full-year 2025. Q4 revenue was approximately $166.0M (up 11% sequential, +1% YoY). FY2025 revenue was approximately $642.8M, or $598.7M excluding $44.1M of patent litigation settlement payments, a 2% decrease year‑over‑year on the adjusted basis. Instruments revenue fell sharply (FY instruments ~$56.8M, -39% YoY). Consumables grew to ~$507.2M for the year (+3% YoY). Cash and marketable securities were about $520M at year end. Company will present at the J.P. Morgan Healthcare Conference on Jan 12, 2026.

2 months ago

#TXG 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results

www.stocktitan.net/news/TXG/10x-genomics-an...

0 0 0 0

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response CareDx (Nasdaq: CDNA) and 10x Genomics (Nasdaq: TXG) launched ImmuneScape, a multiomics research program to map immune biology in transplant rejection and therapeutic response.The collaboration will use 10x Xenium spatial and Chromium Flex single cell platforms to profile FFPE biopsy samples at cellular resolution, focusing on antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Insights are intended to support future diagnostic development and to correlate tissue-level immune architecture with clinical outcomes, including response to anti-CD38 therapies.

2 months ago

#TXG #CDNA CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

www.stocktitan.net/news/TXG/care-dx-and-10x...

0 0 0 0

New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region. PLEASANTON, Calif. and SYDNEY, Nov. 18, 2025/ PRNewswire/-- 10 x Genomics, Inc., a leader in single cell and spatial biology, the Garvan Institute of Medical Research in Australia and the University of Tokyo in Japan, today...

4 months ago

#TXG New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium

www.stocktitan.net/news/TXG/new-astra-conso...

0 0 0 0

TopX

@topxmaxs.bsky.social

4 months ago

🚨ANOTHER BANGER‼️

Free vip access for the first 10 to click on the link 🔗 below ⬇️
winible.com/checkout/free-…

Like and subscribe if you tailed❤️👀

#PrizePicks #NBA #TXG #gamblingX

0 0 0 0

Understanding 10x Genomics' Q3 2025 Performance and Future Outlook 10x Genomics has released its financial results for Q3 2025, showing revenue trends, product innovations, and future prospects for growth.

4 months ago

Understanding 10x Genomics' Q3 2025 Performance and Future Outlook #United_States #financial_results #Pleasanton #10x_Genomics #TXG

0 0 0 0

TopX

@topxmaxs.bsky.social

4 months ago

We can all agree on this right?

Lmk what you think 🤔in the comments 👇

#PrizePicks #NBA #TXG #gamblingX

0 0 0 1

Being Exponential | Luke Lango

@beingexponential.bsky.social

5 months ago

#TXG is collaborating with Anthropic to allow biologists to query their datasets using plain English. This opens up TXG's powerful research tools to a much wider audience and enables scientists to focus more of their effort on scientific discovery rather than technical matters.

0 0 1 0

10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences 10x Genomics (Nasdaq: TXG) and Anthropic announced on October 20, 2025 a collaboration to integrate 10x single cell and spatial analysis tools into Claude for Life Sciences using the Model Context Protocol (MCP).The integration enables researchers to run common workflows—aligning reads, generating Feature Barcode matrices, clustering and other secondary analyses—via natural-language conversation rather than code, and connects Claude to 10x Cloud Analysis for scalable, large‑scale datasets.

5 months ago

#TXG 10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences

www.stocktitan.net/news/TXG/10x-genomics-an...

0 0 0 0

1,500 Patients Worldwide: 10x Genomics' Groundbreaking Study Could End Painful Bone Marrow Tests 3-year PERIBLOOD trial across global sites will evaluate single cell RNA sequencing as alternative to bone marrow aspiration for blood disorders. Study spans 5 continents with 1,500 participants.

6 months ago

#TXG CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics

www.stocktitan.net/news/TXG/cliseq-10x-geno...

0 0 0 0

First-Ever Single-Run RNA and Protein Analysis: 10x Genomics Revolutionizes Spatial Biology Research 10x Genomics introduces Xenium Protein platform enabling simultaneous RNA and protein detection in single cells. First fully integrated spatial multiomic workflow streamlines cancer and immunology research.

7 months ago

#TXG 10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

www.stocktitan.net/news/TXG/10x-genomics-la...

2 0 0 0

10x Genomics Announces a Strong Financial Performance for Q2 2025 10x Genomics has reported impressive financial results for the second quarter of 2025, achieving significant revenue and unveiling strategic initiatives.

7 months ago

10x Genomics Announces a Strong Financial Performance for Q2 2025 #United_States #Pleasanton #10x_Genomics #TXG #Scale_Biosciences

0 0 0 0

10x Genomics Reports Second Quarter 2025 Financial Results Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million. Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million, representing a $20 million increase over the prior quarter. Entered into a definitive agreement to acquire...

7 months ago

#TXG 10x Genomics Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/TXG/10x-genomics-re...

0 0 0 0

10x Genomics Teams With A*STAR to Analyze 2,500 Cancer Samples Using AI-Powered Spatial Biology New AI-driven spatial biology study targets breakthrough cancer discoveries. Partnership analyzes 2,500 tissue samples using advanced Xenium platform. See research details.

8 months ago

#TXG 10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

www.stocktitan.net/news/TXG/10x-genomics-an...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

10 months ago

www.fool.com/investing/2025/05/23/why...

#TXG #a8ffefba-d4cf-45bf-9867-8de855184d1d #investing

Result Details

0 0 0 0

10x Genomics Wins Massive $68M Settlement Plus Royalties in Major Patent Battle with Bruker $68M settlement plus ongoing royalties resolves global patent dispute. See how this deal impacts 10x Genomics' spatial biology leadership and future innovation pipeline.

10 months ago

#TXG 10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

www.stocktitan.net/news/TXG/10x-genomics-an...

0 0 0 0

10x Genomics Reveals First Quarter Financial Performance for 2025 10x Genomics, Inc. has shared its financial results for Q1 2025, highlighting a revenue decrease amidst operational changes and new partnerships.

10 months ago

10x Genomics Reveals First Quarter Financial Performance for 2025 #USA #biotechnology #Pleasanton #10x_Genomics #TXG

0 0 0 0

10x Genomics Reports First Quarter 2025 Financial Results 10x Genomics (TXG) reported mixed Q1 2025 financial results. Revenue reached $154.9 million, including $16.8 million from a patent litigation settlement. Excluding this settlement, revenue was $138.1 million, representing a 2% decrease from Q1 2024, mainly due to lower instrument sales. The company reported a net loss of $34.4 million, improved from a $59.9 million loss in Q1 2024. Gross margin increased to 68% (64% excluding settlement). To strengthen its financial position, 10x announced cost-cutting measures, including reducing operating expenses by $50 million and cutting approximately 8% of its global workforce. Due to uncertainty in U.S. academic and government research funding, the company withdrew its full-year guidance and switched to quarterly guidance, projecting Q2 2025 revenue between $138-142 million.

10 months ago

#TXG 10x Genomics Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/TXG/10x-genomics-re...

0 0 0 0